<DOC>
	<DOCNO>NCT00722254</DOCNO>
	<brief_summary>To determine prevalence myelofibrosis patient primary pulmonary hypertension , discover fibrosis patient primary ( AMM ) secondary .</brief_summary>
	<brief_title>Reversible Secondary Myelofibrosis Clonal Myeloproliferative Disorder</brief_title>
	<detailed_description>Pulmonary arterial hypertension : Pulmonary arterial hypertension ( PAH ) disease primarily affect small precapillary pulmonary vessel . It characterize sustained elevation pulmonary vascular resistance ( PVR ) . Without therapy , right heart failure death eventually occur . PAH occur idiopathic form , primary pulmonary hypertension ( PPH ) , association disorder connective tissue disease congenital heart disease ( CHD ) . PAH remain disease unknown etiology . Until recently , prognosis PAH poor , median survival le 3 year . Prostacyclin ( PGI2 ) main product arachidonic acid vascular endothelium . It potent vasodilator vascular bed . In addition , potent endogenous inhibitor platelet aggregation smooth muscle growth . The prostacyclin receptor ( IP ) locate variety cell type , enable prostacyclin exert range biologic action mean raise intracellular level cAMP activation adenylate cyclase . The stable , freeze-dried salt preparation prostacyclin know epoprostenol available IV administration brand name Flolan ( Glaxo Wellcome , Research Triangle Park , N.C. ) . The first randomized clinical trial PPH show epoprostenol improve quality life , hemodynamics , exercise tolerance , survival 12-week period . Epoprostenol become standard care patient advance PPH . Recently , chronic intravenous epoprostenol show effective therapy improve long-term quality life survival patient PPH . Epoprostenol also improve hemodynamics , exercise capacity , quality life ( survival ) PAH associate CHD connective tissue disease . Side effect epoprostenol infusion include rash , headache , jaw pain , leg pain , diarrhea , nausea , catheter infection , chest pain , anxiety dizziness , bradycardia , dyspnea , abdominal pain , musculoskeletal pain , tachycardia , flu-like symptom , anxiety/nervousness . Thrombocytopenia commonly see patient PPH treat PG12 . Occasionally , decrease blood cell line occur lead anemia pancytopenia . Splenomegaly hypersplenism observe time . While thrombocytopenia attribute antiplatelet effect prostacyclin , pathophysiology pancytopenia poorly understood . There study address thrombocytopenia hemopoietic abnormality people pulmonary hypertension receive epoprostenol . The possibility myelofibrosis cause hematologic abnormality investigate . Primary myelofibrosis myeloproliferative disorder , characterize typically pancytopenia , splenomegaly , leukoerythroblastic blood smear , fibrosis bone marrow examination , myeloid metaplasia . Like myeloproliferative disorder , due somatic mutation clonal proliferation hematopoietic progenitor . Fibrosis occur secondary cytokine secrete malignant cell . These patient symptomatic cytopenia . Bone marrow failure transformation acute myeloid leukemia major reason mortality patient . Elevated blood level hematopoietic progenitor ( identify positivity CD34 antigen ) well document correlate prognosis . Therefore two major identify feature primary myelofibrosis oppose secondary fibrosis marrow : 1 ) clonal hematopoiesis 2 ) high CD 34 positive hematopoietic precursor . We therefore hypothesize two normal patient secondary myelofibrosis help u distinguish two entity . Clonality Studies : Clonality base principal X-chromosome inactivation thus , clonality study female use subject . It base principal female cell two X-chromosomes , one randomly inactivate early embryonic development thus female tissue mixture cell express either paternal maternal inherit x-chromosome gene . In first step , DNA analysis study 5 exonic polymorphism X-chromosome gene previously show useful purpose . If five locus heterozygous subject say informative clonality . Studies proceed follow : The fresh blood platelet granulocytes isolated RNA isolate use later reverse transcription cDNA analyze X-chromosome allelic usage ratio single-stranded conformational polymorphism ( SSCP ) . If one allele express platelet granulocytes patient say clonal favor diagnosis myeloproliferative disorder ( AMM ) , polyclonal blood ( X-chromosome allele express platelet granulocyte ) compatible secondary myelofibrosis . A three-color direct immunofluorescent stain method use evaluation CD34+ cell . In preliminary experience observe four Flolan treat patient PPH splenomegaly , anemia and/or thrombocytopenia . All patient severe marrow fibrosis . The purpose study determine whether incidence bone marrow fibrosis patient population primary secondary , whether secondary effect fibrosis would expect transient resolve discontinuation Flolan . Participating subject Patients undergo follow study : 1 . History Physical examination 2 . Peripheral blood smear 3 . Bone marrow examination determine presence severity fibrosis . The bone marrow specimen take diagnostic purpose examine three independent hematologists/hematopathologists mask fashion presence fibrosis use routine method . 4 . Blood : 30 cc blood collect 1 . Clonality study ( female subject ) , 2 . CD34 quantitation . 3 . Further study do monitor aberrant trafficking hemopoietic stem cell , adhesion molecule , disease relate gene , JAK2V617F cMPL , indicate . 4 . The study repeat patient undergo lung transplant 3 month , 6 month 1 year transplantation .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>1 . &gt; 18 year age 2 . Signed Informed Consent 3 . Subjects diagnose Primary Pulmonary Hypertension Myelofibrosis ( primary secondary ) 1 . Anyone meeting inclusion criterion 2 . Pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Myeloproliferative Disorder</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>Primary Pulmonary Hypertension</keyword>
	<keyword>Secondary Myelofibrosis</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>Flolan</keyword>
	<keyword>Clonality</keyword>
	<keyword>CD34+ cell</keyword>
	<keyword>Hematologic abnormality</keyword>
</DOC>